Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Last Updated: January 28, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Talinolol

See Plans and Pricing

« Back to Dashboard

What is the drug development status for Talinolol?

Talinolol is an investigational drug.

There have been 4 clinical trials for Talinolol. The most recent clinical trial was a Phase 1 trial, which was initiated on April 1st 2011.

The most common disease conditions in clinical trials are Obesity, Morbid and [disabled in preview]. The leading clinical trial sponsors are University Medicine Greifswald, Institut fuer anwendungsorientierte Forschung und klinische Studien GmbH, and Matthias Schwab.

There are three hundred and eighty-one US patents protecting this investigational drug and three international patents.

Recent Clinical Trials for Talinolol
Open Label Study for the Functional Characterization of Drug Metabolism and TransportMatthias SchwabPhase 1
Absorption of Paracetamol, Talinolol and Amoxicillin After Oral Administration Using Non-caloric and Caloric WaterUniversity Medicine GreifswaldPhase 1
Repeated Dose Study for the Investigation of Heritability of and Genetic Influences on Drug PharmacokineticsInstitut fuer anwendungsorientierte Forschung und klinische Studien GmbHPhase 1

See all Talinolol clinical trials

Clinical Trial Summary for Talinolol

Top disease conditions for Talinolol
Top clinical trial sponsors for Talinolol

See all Talinolol clinical trials

US Patents for Talinolol

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Talinolol   Start Trial Drug device configured for wireless communication Pop Test Abuse Deterrent Technology, LLC (Cliffside Park, NJ)   Start Trial
Talinolol   Start Trial Inhalable pharmaceutical compositions iCeutica Pty Ltd. (Iluka, WA, AU)   Start Trial
Talinolol   Start Trial Pyrimidines as sodium channel blockers Purdue Pharma L.P. (Stamford, CT)   Start Trial
Talinolol   Start Trial Compounds that are ERK inhibitors Merck, Sharp & Dohme Corp. (Rahway, NJ)   Start Trial
Talinolol   Start Trial Sulfoximine substituted quinazolines for pharmaceutical compositions EVOTEC INTERNATONAL GMBH (DE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Talinolol

Drugname Country Document Number Estimated Expiration Related US Patent
Talinolol European Patent Office 3151906 2034-06-03   Start Trial
Talinolol World Intellectual Property Organization (WIPO) 2015187289 2034-06-03   Start Trial
Talinolol Australia 2013227351 2032-02-28   Start Trial
Talinolol Australia 2016202881 2032-02-28   Start Trial
Talinolol Australia 2017213466 2032-02-28   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.